Fig. 5: Effects of PLX3397 on antidepressant effects of (R)-ketamine in a CSDS model. | Translational Psychiatry

Fig. 5: Effects of PLX3397 on antidepressant effects of (R)-ketamine in a CSDS model.

From: Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Fig. 5

a Chronic social defeat stress (CSDS) was performed from day 1 to day 10 for 10 days. Social interaction test was performed on day 11. On day 12, vehicle or PLX3397 was administered i.c.v. to CSDS susceptible mice. On day 13, saline or (R)-ketamine (10 mg/kg) was administered i.p. 24 h after injection of PLX3397. Locomotion and FST were performed 1 and 3 h after injection, respectively. FST and SPT were performed 1 and 2 days after injection, respectively. b Locomotion (1 h, one-way ANOVA, F4,35 = 0.226, P = 0.921). c TST (3 h, one-way ANOVA, F4,35  = 13.706, P < 0.001). d FST (1 day, one-way ANOVA, F4,35 = 5.362, P = 0.005). e SPT (2 day, one-way ANOVA, F4,35 = 6.045, P = 0.003). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. ANOVA analysis of variance, FST forced swimming test, N.S. not significant, PLX PLX3397, R-KT (R)-ketamine, SPT sucrose preference test, TST tail suspension test.

Back to article page